PLX4032 (Vemurafenib) Clinical Trials

Size	Price	Qty
10mg	USD 147
50mg	USD 270

Clinical Trials

Numerous clinical trials spanning Early Phase 1 through Phase 3 evaluate vemurafenib across oncological indications, including metastatic melanoma, papillary thyroid carcinoma, hairy cell leukemia, non-small-cell lung carcinoma, and BRAF-mutated solid tumors. Sponsored by major pharmaceutical companies and academic institutions, these studies range from early safety evaluations to large randomized confirmatory trials. Across this research landscape, trial statuses include actively recruiting, completed, active non-recruiting, and terminated protocols.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05768178	RECRUITING	Haematological Malignancy; Melanoma; Thyroid Cancer, Papillary; Ovarian Neoplasms; Colorectal Neoplasms; Laryngeal Neoplasms; Carcinoma, Non-Small-Cell Lung; Glioma; Multiple Myeloma; Erdheim-Chester Disease; Thyroid Carcinoma, Anaplastic; Solid Tumour	Cancer Research UK	2023-03-01	PHASE2; PHASE3
NCT05722886	RECRUITING	Haematological Malignancy; Solid Tumour	Cancer Research UK	2023-03-01	PHASE2; PHASE3
NCT04341181	RECRUITING	Cancer; Tumors; Neoplasms; Neoplasia	Ulrik Lassen	2020-08-24	PHASE2
NCT03768063	ACTIVE_NOT_RECRUITING	Cancer	Hoffmann-La Roche	2019-02-28	PHASE3
NCT06692491	NOT_YET_RECRUITING	Rare Tumour	Peking University Shenzhen Hospital	2025-01-01	PHASE2
NCT02693535	RECRUITING	Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors	American Society of Clinical Oncology	2016-03-14	PHASE2
NCT06561360	RECRUITING	Hairy Cell Leukemia	Memorial Sloan Kettering Cancer Center	2024-09-09	PHASE2
NCT02925234	RECRUITING	Cancer; Tumors; Neoplasm; Neoplasia	The Netherlands Cancer Institute	2016-08	PHASE2
NCT03181100	ACTIVE_NOT_RECRUITING	Metastatic Thyroid Gland Carcinoma; Poorly Differentiated Thyroid Gland Carcinoma; Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8; Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8; Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8; Thyroid Gland Anaplastic Carcinoma; Unresectable Thyroid Gland Carcinoma	M.D. Anderson Cancer Center	2017-07-27	PHASE2
NCT04943198	RECRUITING	Histiocytosis	Anna Raciborska	2021-04-01	PHASE2
NCT04943224	RECRUITING	Histiocytosis	Anna Raciborska	2021-04-01	PHASE2
NCT03178552	ACTIVE_NOT_RECRUITING	Non-Small Cell Lung Cancer	Hoffmann-La Roche	2017-09-22	PHASE2; PHASE3
NCT03410875	ACTIVE_NOT_RECRUITING	Hairy Cell Leukemia; Leukemia; Leukemia, Hairy Cell	Memorial Sloan Kettering Cancer Center	2018-02-09	PHASE2
NCT03297606	RECRUITING	Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors	Canadian Cancer Trials Group	2018-03-23	PHASE2
NCT06008119	RECRUITING	Colorectal Cancer Metastatic	Shanghai Kechow Pharma, Inc.	2023-10-25	PHASE3
NCT04302025	RECRUITING	Non-small Cell Lung Cancer	Genentech, Inc.	2020-11-06	PHASE2
NCT05159245	RECRUITING	Advanced Cancer; Solid Tumor; Haematological Malignancy	Helsinki University Central Hospital	2021-12-10	PHASE2
NCT06440850	RECRUITING	Thyroid Gland Follicular Carcinoma; Thyroid Gland Oncocytic Carcinoma; Thyroid Gland Papillary Carcinoma	City of Hope Medical Center	2024-07-15	PHASE2
NCT01709292	ACTIVE_NOT_RECRUITING	Thyroid Cancer	M.D. Anderson Cancer Center	2012-11-07	PHASE2
NCT06603376	RECRUITING	Colorectal Carcinoma	Shanghai Changzheng Hospital	2024-09-01	PHASE2
NCT04423185	RECRUITING	Rare Tumor	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	2020-08-15	PHASE2
NCT05238831	WITHDRAWN	Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Recurrent Adult Soft Tissue Sarcoma; Recurrent Breast Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8	OHSU Knight Cancer Institute	2023-01-30	EARLY_PHASE1
NCT05388123	COMPLETED	Hairy Cell Leukemia	Scripps Health	2022-03-02	PHASE2
NCT02314481	COMPLETED	Non-small Cell Lung Cancer	University College, London	2017-05-12	PHASE2
NCT05900219	UNKNOWN	Non-small-cell Lung Cancer	Shanghai Kechow Pharma, Inc.	2023-09-24	PHASE2
NCT01638676	RECRUITING	Melanoma	University of Louisville	2012-07	PHASE1; PHASE2
NCT03554083	COMPLETED	Clinical Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8	Mayo Clinic	2018-10-05	PHASE2
NCT03155620	ACTIVE_NOT_RECRUITING	Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Histiocytic Sarcoma; Juvenile Xanthogranuloma; Langerhans Cell Histiocytosis; Malignant Glioma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Ependymoma; Recurrent Ewing Sarcoma; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Primary Central Nervous System Neoplasm; Recurrent Rhabdoid Tumor; Recurrent Soft Tissue Sarcoma; Refractory Ewing Sarcoma; Refractory Glioma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Peripheral Primitive Neuroectodermal Tumor; Refractory Primary Central Nervous System Neoplasm; Refractory Rhabdoid Tumor; Refractory Rhabdomyosarcoma; Rhabdoid Tumor; Stage III Osteosarcoma AJCC v7; Stage III Soft Tissue Sarcoma AJCC v7; Stage IV Osteosarcoma AJCC v7; Stage IV Soft Tissue Sarcoma AJCC v7; Stage IVA Osteosarcoma AJCC v7; Stage IVB Osteosarcoma AJCC v7; Wilms Tumor	National Cancer Institute (NCI)	2017-07-31	PHASE2
NCT04551521	COMPLETED	Metastatic or Locally Advanced Malignancies	German Cancer Research Center	2021-10-13	PHASE2
NCT04591431	UNKNOWN	Breast Cancer; Gastrointestinal Cancer; Non Small Cell Lung Cancer; Other Cancer	Fondazione per la Medicina Personalizzata	2020-10-07	PHASE2
NCT02145143	COMPLETED	Thyroid Carcinoma	Memorial Sloan Kettering Cancer Center	2014-05-20	EARLY_PHASE1
NCT05068752	COMPLETED	Pancreas Cancer	HonorHealth Research Institute	2021-10-28	PHASE2
NCT05263453	UNKNOWN	Melanoma	Shanghai Kechow Pharma, Inc.	2021-09-06	PHASE2
NCT01711632	COMPLETED	Hairy Cell Leukemia	Memorial Sloan Kettering Cancer Center	2012-10	PHASE2
NCT02902029	COMPLETED	Malignant Melanoma	University Hospital, Essen	2016-11	PHASE2
NCT02036086	UNKNOWN	Melanoma	Sunnybrook Health Sciences Centre	2015-08	PHASE2
NCT05233332	UNKNOWN	CRC	Shanghai Kechow Pharma, Inc.	2022-02-24	PHASE2
NCT04722575	ACTIVE_NOT_RECRUITING	Melanoma	Fondazione Melanoma Onlus	2020-12-03	PHASE2
NCT03781219	UNKNOWN	Solid Tumor	Shanghai Kechow Pharma, Inc.	2018-07-01	PHASE1
NCT04462471	COMPLETED	Thyroid Carcinoma; Thyroid Cancer; Thyroid Cancer, Follicular; Thyroid Cancer (Follicular Cell); Thyroid Cancer, Papillary; BRAF V600E Mutation Positive	Memorial Sloan Kettering Cancer Center	2020-06-26	PHASE1
NCT03224767	ACTIVE_NOT_RECRUITING	BRAF V600E Mutation Present; Papillary Craniopharyngioma	Alliance for Clinical Trials in Oncology	2018-01-05	PHASE2
NCT03239015	UNKNOWN	Rare Tumor; Refractory Tumor	Baodong Qin	2017-01-01	PHASE2
NCT02091141	COMPLETED	Neoplasms; Solid Tumors; Biliary Cancer; Salivary Cancer; Bladder Cancer	Genentech, Inc.	2014-04-14	PHASE2
NCT03514901	UNKNOWN	Melanoma Metastatic; BRAF V600 Mutation	Intergruppo Melanoma Italiano	2018-06-18	PHASE2
NCT03585686	UNKNOWN	Langerhans Cell Histiocytosis	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	2018-06-26	PHASE2
NCT05768178	Recruiting	Solid Tumor\|Haematological Malignancy\|Melanoma\|Thyroid Cancer Papillary\|Ovarian Neoplasms\|Colorectal Neoplasms\|Laryngeal Neoplasms\|Carcinoma Non-Small-Cell Lung\|Glioma\|Multiple Myeloma\|Erdheim-Chester Disease\|Thyroid Carcinoma Anaplastic	Cancer Research UK\|University of Manchester\|University of Birmingham\|Royal Marsden NHS Foundation Trust\|Hoffmann-La Roche	2023-03-01	Phase 2\|Phase 3
NCT03498521	COMPLETED	Cancer of Unknown Primary Site	Hoffmann-La Roche	2018-07-10	PHASE2
NCT03430947	TERMINATED	Malignant Melanoma Stage IV; BRAF V600 Mutation; Brain Metastases	Technische Universität Dresden	2018-07-01	PHASE2
NCT04801966	TERMINATED	Cancer	Peter MacCallum Cancer Centre, Australia	2021-09-23
NCT02968303	UNKNOWN	Melanoma, Malignant, of Soft Parts	Radboud University Medical Center	2017-01-27	PHASE2
NCT05540951	UNKNOWN	Colorectal Cancer	Fudan University	2018-06-01	PHASE3
NCT05019534	UNKNOWN	BRAF V600E-mutated /MSS Metastatic Colorectal Cancer; Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody	West China Hospital	2021-08-15	PHASE1
NCT01843738	WITHDRAWN	BRAFV600 Mutation; Stage IV Melanoma	University of Utah	2017-06	PHASE1
NCT03220035	COMPLETED	Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma; Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma; Ependymoma; Ewing Sarcoma; Hepatoblastoma; Langerhans Cell Histiocytosis; Malignant Germ Cell Tumor; Malignant Glioma; Osteosarcoma; Peripheral Primitive Neuroectodermal Tumor; Recurrent Childhood Central Nervous System Neoplasm; Recurrent Childhood Non-Hodgkin Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Refractory Malignant Solid Neoplasm; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Primary Central Nervous System Neoplasm; Rhabdoid Tumor; Rhabdomyosarcoma; Soft Tissue Sarcoma; Wilms Tumor	National Cancer Institute (NCI)	2017-11-08	PHASE2
NCT01787500	COMPLETED	BRAF NP_004324.2:p.V600X; KRAS wt Allele; Metastatic Malignant Solid Neoplasm; Stage IV Colorectal Cancer AJCC v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7; Unresectable Solid Neoplasm	M.D. Anderson Cancer Center	2013-02-15	PHASE1
NCT04790448	COMPLETED	Colorectal Cancer Metastatic	Sun Yat-sen University	2020-07-27	PHASE1; PHASE2
NCT03727763	UNKNOWN	Colorectal Cancer	Shanghai Changzheng Hospital	2018-10-08	PHASE2
NCT02638428	UNKNOWN	Relapsed Pediatric Solid Tumor; Refractory Pediatric Solid Tumor; Relapsed Pediatric AML; Refractory Pediatric AML	Samsung Medical Center	2015-12	PHASE2
NCT01659151	COMPLETED	Metastatic Melanoma	H. Lee Moffitt Cancer Center and Research Institute	2012-08-03	PHASE2
NCT05068752	Recruiting	Pancreas Cancer	HonorHealth Research Institute\|Bayer\|Genentech Inc.	2021-10-28	Phase 2
NCT03625141	COMPLETED	Metastatic Melanoma	Hoffmann-La Roche	2018-12-13	PHASE2
NCT01531361	COMPLETED	Advanced Malignant Neoplasm; BRAF Gene Mutation; Metastatic Malignant Neoplasm; Recurrent Malignant Neoplasm; Refractory Malignant Neoplasm	M.D. Anderson Cancer Center	2012-02-06	PHASE1
NCT03878524	TERMINATED	Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Anatomic Stage IV Breast Cancer AJCC v8; Anemia; Ann Arbor Stage III Hodgkin Lymphoma; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Castration-Resistant Prostate Carcinoma; Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Hematopoietic and Lymphoid System Neoplasm; Locally Advanced Pancreatic Adenocarcinoma; Metastatic Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Pancreatic Adenocarcinoma; Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Primary Myelofibrosis; Recurrent Acute Lymphoblastic Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Recurrent Hematologic Malignancy; Recurrent Hodgkin Lymphoma; Recurrent Myelodysplastic Syndrome; Recurrent Myelodysplastic/Myeloproliferative Neoplasm; Recurrent Myeloproliferative Neoplasm; Recurrent Non-Hodgkin Lymphoma; Recurrent Plasma Cell Myeloma; Recurrent Small Lymphocytic Lymphoma; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Myeloid Leukemia; Refractory Chronic Lymphocytic Leukemia; Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Refractory Chronic Myelomonocytic Leukemia; Refractory Hematologic Malignancy; Refractory Hodgkin Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Myelodysplastic Syndrome; Refractory Myelodysplastic/Myeloproliferative Neoplasm; Refractory Non-Hodgkin Lymphoma; Refractory Plasma Cell Myeloma; Refractory Primary Myelofibrosis; Refractory Small Lymphocytic Lymphoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8; Unresectable Pancreatic Adenocarcinoma	OHSU Knight Cancer Institute	2020-04-01	PHASE1
NCT02414750	TERMINATED	Metastatic Melanoma	Netherlands Working Group on Immunotherapy of Oncology	2014-12	PHASE2
NCT03013491	TERMINATED	Solid Tumor; Lymphoma	CytomX Therapeutics	2017-01-19	PHASE1; PHASE2
NCT03101254	COMPLETED	Melanoma	Dana-Farber Cancer Institute	2017-06-06	PHASE1; PHASE2
NCT03224208	TERMINATED	Melanoma; Melanoma (Skin); Melanoma Stage	Fondazione Melanoma Onlus	2018-05-17	PHASE2
NCT01596140	COMPLETED	Advanced Cancer; Solid Tumor	M.D. Anderson Cancer Center	2012-12-18	PHASE1
NCT02303951	TERMINATED	Malignant Melanoma	University Hospital Tuebingen	2015-01-22	PHASE2
NCT01636622	COMPLETED	Advanced Cancers	M.D. Anderson Cancer Center	2012-07-09	PHASE1
NCT01656642	COMPLETED	Malignant Melanoma	Genentech, Inc.	2012-08-13	PHASE1
NCT01739764	COMPLETED	Neoplasms	Hoffmann-La Roche	2013-02-19	PHASE4
NCT02537600	COMPLETED	Malignant Melanoma	Center Eugene Marquis	2015-12	PHASE2
NCT02721459	ACTIVE_NOT_RECRUITING	Melanoma; Skin Cancer	H. Lee Moffitt Cancer Center and Research Institute	2016-09-07	PHASE1
NCT02908672	COMPLETED	Melanoma	Hoffmann-La Roche	2017-01-13	PHASE3
NCT02583516	COMPLETED	Melanoma	Grupo Español Multidisciplinar de Melanoma	2015-06-30	PHASE2
NCT02818023	TERMINATED	Melanoma	Yana Najjar	2016-07-13	PHASE1
NCT02145910	WITHDRAWN	Recurrent Melanoma; Stage IV Melanoma; Tumors Metastatic to Brain	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University		PHASE1
NCT02291289	COMPLETED	Colorectal Cancer	Hoffmann-La Roche	2015-04-17	PHASE2
NCT01898585	COMPLETED	Malignant Melanoma	Hoffmann-La Roche	2013-10-17	PHASE4
NCT02304809	ACTIVE_NOT_RECRUITING	Solid Tumors; Hematologic Cancers; Metastatic Cancers	UNICANCER	2014-10-13	PHASE2
NCT02354690	COMPLETED	Metastatic Melanoma	Inge Marie Svane	2014-11	PHASE1; PHASE2
NCT01748149	COMPLETED	Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas	University of California, San Francisco	2014-04-29	EARLY_PHASE1
NCT02608034	COMPLETED	Metastatic Melanoma, BRAF V600 Mutation Positive	Genentech, Inc.	2016-05-26	PHASE1
NCT01876641	TERMINATED	Metastatic Melanoma; Melanoma; BRAF-mutated Metastatic Melanoma; V600EBRAF-mutated Metastatic Melanoma	Mohammed M Milhem	2013-10	PHASE1
NCT01959633	COMPLETED	Melanoma	Fondazione Melanoma Onlus	2014-04-03	PHASE1; PHASE2
NCT03005639	WITHDRAWN	Stage IIIB-C Melanoma	Inova Health Care Services	2017-06-01	PHASE2
NCT03410875	Active not recruiting	Hairy Cell Leukemia\|Leukemia\|Leukemia Hairy Cell	Memorial Sloan Kettering Cancer Center\|Dana-Farber Cancer Institute\|Yale University	2018-02-09	Phase 2
NCT01636908	COMPLETED	Cancer; Advanced Solid Tumors	Amsterdam UMC, location VUmc	2011-08
NCT02768207	COMPLETED	Metastatic Melanoma	Hoffmann-La Roche	2016-05-23	PHASE2
NCT03108209	COMPLETED	Phototoxicity	Michele Sayag	2016-07
NCT02164916	COMPLETED	Colorectal Cancer	SWOG Cancer Research Network	2014-11	PHASE2
NCT01603212	COMPLETED	Melanoma	M.D. Anderson Cancer Center	2013-07-18	PHASE1
NCT02115035	WITHDRAWN	Multiple Myeloma	University of Arkansas	2014-07	PHASE1; PHASE2
NCT01667419	COMPLETED	Melanoma	Hoffmann-La Roche	2012-09-24	PHASE3
NCT01767623	COMPLETED	Neoplasms	Hoffmann-La Roche	2013-08-20	PHASE1
NCT03013491	Completed	Solid Tumor\|Lymphoma	CytomX Therapeutics	2017-01	Phase 1\|Phase 2
NCT01909453	COMPLETED	Melanoma	Pfizer	2013-09-12	PHASE3
NCT01943422	COMPLETED	Melanoma	John Kirkwood	2013-10	PHASE1
NCT02427893	WITHDRAWN	Melanoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	2015-08	PHASE3
NCT02202200	UNKNOWN	Melanoma BRAF V600E/K Mutated; CDNKN2A Loss Defined	Assistance Publique - Hôpitaux de Paris	2014-05	PHASE1; PHASE2
NCT01524978	COMPLETED	Multiple Myeloma, Neoplasms	Hoffmann-La Roche	2012-04-12	PHASE2
NCT02456701	COMPLETED	Thyroid Cancer	Celldex Therapeutics	2015-06	PHASE1
NCT01771458	COMPLETED	Reccurent/Metastatic Solid Tumor Disease	Institut Curie	2012-10	PHASE2
NCT01657591	COMPLETED	Melanoma	H. Lee Moffitt Cancer Center and Research Institute	2012-07-27	PHASE1
NCT02441465	COMPLETED	Malignant Melanoma, Cancer	Hoffmann-La Roche	2015-08-13	PHASE1
NCT01813214	TERMINATED	Melanoma	Georgetown University	2013-03	PHASE2
NCT01585415	TERMINATED	Metastatic Cancer; Melanoma	National Cancer Institute (NCI)	2012-04-09	PHASE1
NCT01897116	COMPLETED	Melanoma	Abramson Cancer Center at Penn Medicine	2013-06	PHASE1
NCT02230306	TERMINATED	Active Melanoma Brain Metastases	Melissa Burgess, MD	2015-02	PHASE2
NCT01307397	COMPLETED	Malignant Melanoma	Hoffmann-La Roche	2011-03-01	PHASE3
NCT01495988	TERMINATED	Melanoma; Metastatic Melanoma	Melanoma Research Foundation Breakthrough Consortium	2013-08	PHASE2
NCT01519323	TERMINATED	Malignant Melanoma	Hoffmann-La Roche	2013-01	PHASE1
NCT02068079	WITHDRAWN	Melanoma	Duke University	2014-04	PHASE1
NCT01765543	COMPLETED	Malignant Melanoma, Neoplasms	Hoffmann-La Roche	2013-07	PHASE1
NCT01942993	TERMINATED	Melanoma	Philip Friedlander	2013-09	PHASE2
NCT01378975	COMPLETED	Malignant Melanoma	Hoffmann-La Roche	2011-07	PHASE2
NCT00405587	COMPLETED	Malignant Melanoma; Colorectal Carcinoma	Plexxikon	2006-11	PHASE1
NCT01586195	TERMINATED	Malignant Melanoma	Genentech, Inc.	2011-10-31	PHASE2
NCT01791309	COMPLETED	Metastatic Colorectal Cancer	Memorial Sloan Kettering Cancer Center	2013-01	PHASE1
NCT01841463	SUSPENDED	Advanced or Inoperable Malignant Melanoma With BRAF Mutation	Piramal Enterprises Limited	2013-08	PHASE1
NCT01673737	COMPLETED	Neoplasm Malignant	Sanofi	2012-08	PHASE1
NCT01754376	TERMINATED	Melanoma	Massachusetts General Hospital	2013-01	PHASE2
NCT02050321	TERMINATED	Malignant Melanoma	University of Arizona	2013-12	PHASE2
NCT01616199	TERMINATED	Advanced BRAF-mutant Cancers	Cascadian Therapeutics Inc.	2012-08	PHASE1; PHASE2
NCT02052193	TERMINATED	Metastatic Melanoma (Carrying BRAF V600 Mutation)	University Hospital Tuebingen	2014-01	PHASE2
NCT01683188	TERMINATED	Metastatic Melanoma	Clinigen, Inc.	2012-08	PHASE4
NCT01286753	COMPLETED	Neoplasms	Hoffmann-La Roche	2011-06	PHASE2
NCT01826448	TERMINATED	V600-mutated BRAF Unresectable Melanoma; V600-mutated BRAF Metastatic Melanoma; Stage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor	Daiichi Sankyo	2013-11-05	PHASE1
NCT01835184	TERMINATED	Recurrent Melanoma; Stage IIIA Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma; Unspecified Adult Solid Tumor, Protocol Specific	National Cancer Institute (NCI)	2013-05	PHASE1
NCT02077114	COMPLETED	Malignant Melanoma With Metastasis	Herlev Hospital	2014-02	PHASE1
NCT01844674	COMPLETED	Malignant Melanoma, Neoplasms	Hoffmann-La Roche	2013-09-02	PHASE1
NCT01673854	COMPLETED	Melanoma	Bristol-Myers Squibb	2012-09-13	PHASE2
NCT01974258	WITHDRAWN	Neoplasms	Hoffmann-La Roche	2014-02	PHASE1
NCT01781026	COMPLETED	Melanoma	Yale University	2013-04	PHASE2
NCT01851824	COMPLETED	Malignant Melanoma, Neoplasms	Hoffmann-La Roche	2013-08	PHASE1
NCT01765569	COMPLETED	Malignant Melanoma, Neoplasms	Hoffmann-La Roche	2013-07	PHASE1
NCT01689519	COMPLETED	Malignant Melanoma	Hoffmann-La Roche	2013-01-08	PHASE3
NCT01597908	COMPLETED	Melanoma	Novartis Pharmaceuticals	2012-06-04	PHASE3
NCT01849666	COMPLETED	Malignant Melanoma, Neoplasms	Hoffmann-La Roche	2013-09	PHASE1
NCT01983124	COMPLETED	Malignant Melanoma Stage IV	Paola Queirolo	2013-02	PHASE2
NCT01611675	TERMINATED	Melanoma	Massachusetts General Hospital	2012-07	PHASE1
NCT01512251	COMPLETED	BRAF Mutant Metastatic Melanoma	University of California, San Francisco	2012-06-09	PHASE1; PHASE2
NCT01910181	COMPLETED	Malignant Melanoma	Hoffmann-La Roche	2013-08-17	PHASE1
NCT01271803	COMPLETED	Malignant Melanoma	Hoffmann-La Roche	2011-02-17	PHASE1
NCT01765556	WITHDRAWN	Malignant Melanoma, Neoplasms	Hoffmann-La Roche	2013-10	PHASE1
NCT01519427	TERMINATED	Recurrent Melanoma; Stage IIIA Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma	National Cancer Institute (NCI)	2012-01	PHASE2
NCT01400451	TERMINATED	Melanoma	Bristol-Myers Squibb	2011-11	PHASE1
NCT01474551	TERMINATED	Melanoma	Memorial Sloan Kettering Cancer Center	2011-11	PHASE2
NCT01006980	COMPLETED	Malignant Melanoma	Hoffmann-La Roche	2010-01	PHASE3
NCT00949702	COMPLETED	Malignant Melanoma	Hoffmann-La Roche	2009-09-30	PHASE2

(data from https://clinicaltrials.gov, updated on 2025-11-24)

Check the PLX4032 (Vemurafenib) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Vemurafenib selectively binds to the ATP-binding domain of the mutated BRAF V600E kinase, inhibiting its constitutive enzymatic activity and blocking downstream MEK and ERK phosphorylation within the MAPK pathway. This targeted signaling blockade suppresses tumor cellular proliferation and induces apoptosis, driving tumor regression in clinical trial populations with BRAF V600E-mutated malignancies such as melanoma, hairy cell leukemia, and papillary thyroid carcinoma.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).